Table 3 Treatment-related adverse events (trAEs) occurring ≥5% by the number of patients per dose range for CFI-400945
Dosing cohort | 3–32 mg cohort (n = 21) | 48–64 mg cohort (n = 18) | 72–96 mg cohort (n = 13) | 3–96 mg cohort (n = 52) | |||
|---|---|---|---|---|---|---|---|
Events | Grade 1/2, N (%) | Grade 3/4, N (%) | Grade 1/2, N (%) | Grade 3/4, N (%) | Grade 1/2, N (%) | Grade 3/4, N (%) | All trAEs, N (%) |
Fatigue | 5 (24) | 0 (0) | 9 (50) | 0 (0) | 5 (38) | 0 (0) | 19 (37) |
Nausea | 3 (14) | 0 (0) | 5 (28) | 0 (0) | 6 (46) | 0 (0) | 14 (27) |
Diarrhoea | 4 (19) | 0 (0) | 3 (17) | 1 (6) | 3 (23) | 0 (0) | 11 (21) |
Neutropenia | 0 (0) | 0 (0) | 1 (6) | 3 (17) | 0 (0) | 7 (54) | 11 (21) |
Anorexia | 4 (19) | 0 (0) | 2 (11) | 0 (0) | 4 (31) | 0 (0) | 10 (19) |
Vomiting | 1 (5) | 0 (0) | 1 (6) | 1 (6) | 1 (8) | 0 (0) | 4 (8) |
Dyspepsia | 1 (5) | 0 (0) | 1 (6) | 0 (0) | 1 (8) | 0 (0) | 3 (6) |
Dehydration | 1 (5) | 0 (0) | 1 (6) | 0 (0) | 1 (8) | 0 (0) | 3 (6) |
Hypomagnesaemia | 0 (0) | 0 (0) | 1 (6) | 0 (0) | 2 (15) | 0 (0) | 3 (6) |
